High-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with rituximab in patients with relapsed/refractory or high-risk B-cell NHL

被引：0
|
作者：
Oyan, B [1 ]
Koc, Y [1 ]
Ozdemir, E [1 ]
Kansu, E [1 ]
机构：
[1] Univ Hacettepe, Ankara, Turkey
来源：
BONE MARROW TRANSPLANTATION | 2005年 / 35卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S385 / S385
页数：1
相关论文
共 50 条
  • [21] The addition of Rituximab to high dose sequential chemotherapy (HDS) programs with autologous transplantation significantly improves the outcome of patients with refractory or relapsed B-cell non Hogkin's lymphoma.
    Cortelazzo, S
    Rossi, A
    Carlotti, E
    Viero, P
    Rambaldi, A
    Barbui, T
    BLOOD, 2005, 106 (11) : 589A - 590A
  • [22] Multicenter phase II trial of 90Y-Ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractoried, or high-risk B-cell NHL
    Kang, Byung Woog
    Jo, Jae-Cheol
    Kim, Shin
    Jang, Geundoo
    Lee, Sung Sook
    Sym, Sun Jin
    Ryu, Jin-Sook
    Kim, Won Seog
    Yoon, Sung Soo
    Suh, Cheolwon
    BLOOD, 2007, 110 (11) : 569A - 569A
  • [23] High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)
    Oyan, B
    Koc, Y
    Ozdemir, E
    Kansu, E
    BLOOD, 2004, 104 (11) : 393B - 393B
  • [24] Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia
    Pileckyte, Regina
    Jurgutis, Mindaugas
    Valceckiene, Vilma
    Stoskus, Mindaugas
    Gineikiene, Egle
    Sejoniene, Jurgita
    Degulys, Andrius
    Zvirblis, Tadas
    Griskevicius, Laimonas
    LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1055 - 1065
  • [25] High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL - Preliminary results.
    Gorczynska, E
    Toporski, J
    Boguslawska-Jaworska, J
    Slociak, M
    BONE MARROW TRANSPLANTATION, 1998, 22 : S107 - S109
  • [26] Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
    El Gnaoui, T.
    Dupuis, J.
    Belhadj, K.
    Jais, J.-P.
    Rahmouni, A.
    Copie-Bergman, C.
    Gaillard, I.
    Divine, M.
    Tabah-Fisch, I.
    Reyes, F.
    Haioun, C.
    ANNALS OF ONCOLOGY, 2007, 18 (08) : 1363 - 1368
  • [27] The Efficacy of High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Osteosarcoma
    Sakiyama, Hideki
    Hamada, Satoru
    Yagi, Takeshi
    Miyamoto, Jiro
    Oshiro, Tokiko
    Uehara, Taichi
    Kiyuna, Shinobu
    Tome, Yasunori
    Maehara, Hiroki
    Matsuda, Takehiro
    Higa, Takeshi
    Hyakuna, Nobuyuki
    Nakanishi, Koichi
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S60 - S60
  • [28] Upfront high-dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high-risk diffuse large B-cell lymphoma
    Nakaya, Aya
    Fujita, Shinya
    Satake, Atsushi
    Nakanishi, Takahisa
    Azuma, Yoshiko
    Tsubokura, Yukie
    Hotta, Masaaki
    Yoshimura, Hideaki
    Ishii, Kazuyoshi
    Ito, Tomoki
    Nomura, Shosaku
    ONCOLOGY LETTERS, 2017, 14 (03) : 3803 - 3808
  • [29] Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?
    Feldman, Darren R.
    Motzer, Robert J.
    Bajorin, Dean F.
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (02): : 78 - 79
  • [30] RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
    Sung-Won Kim
    Yoshitaka Asakura
    Kinuko Tajima
    Toshiki Iwai
    Hirofumi Taji
    Takaaki Chou
    Yasuo Morishima
    Junji Suzumiya
    Hisashi Sakamaki
    Ritsuro Suzuki
    Takahiro Fukuda
    International Journal of Hematology, 2020, 111 : 256 - 266
12345